Clinical trial · Observational
Evaluation of Treatment Response With Integrated MRI/PET in Patients With Hepatocellular Carcinoma
NCT02550613CI-TRIAL-00027589unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to explore the ability of integrated MRI/PET to detect and evaluate treatment outcome in HCC patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| The imaging biomarkers determined by MR-PET | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- The recurrence rate at 3 months after treatment
- timeFrame
- 3 months
Secondary outcomes (1)
- measure
- The overall survival after treatment
- timeFrame
- 1 year
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: 1. Prior Informed Consent Form 2. At least one measurable tumor, according to RECIST version 1.1. 3. Age \> 20 years. 4. ECOG performance status 0 or 1. 5. Life expectancy \> 3 months. 6. Confirmed Diagnosis of HCC 7. Adequate renal function (Serum creatinine ≦ 1.5 x upper limit of normal). Exclusion Criteria: 1. Age \<20 years old 2. Pregnancy 3. Contraindication for MRI: claustrophobia or MR non-compatible devices 4. Contraindication for MR contrast medium: severe adverse reaction or impaired renal function (Cre \> 2.0) 5. History of other malignancy
References
Publications (0)
Data not yet available
No reference posted for this study.